Optimising the treatment of gout

Completed

• Conditions: The effectiveness of the co-administration of allopurinol and probenecid in patients with gout; Metabolic and Endocrine - Other inflammatory or immune system disorders

• Registration Number: ACTRN12607000247471
• Lead Sponsor: Department of Clinical Pharmacology and Toxicology, St Vincent’s Hospital Sydney Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-05-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Patients taking allopurinol for the indication of hyperuricaemia and/or gout.

Exclusion Criteria

1. A history of sensitivity to allopurinol or probenecid2. A history of nephrolithiasis3. Patients taking drugs likely to interfere with the pharmacokinetics of allopurinol or probenecid including: salicylates (high doses) 4. Drugs likely to interact with probenecid including: valaciclovir, acyclovir, famiciclovir, penciclovir, ganciclovir, zidovudine, methotrexate, lorazepam, midazolam, nitrazepam. Note: Drugs which may affect plasma urate concentrations need to be taken consistently throughout the study to avoid biasing the plasma urate concentrations.

Study & Design

• Study Type: Interventional
• Study Design: Not specified